Generative deep learning discovers the RIPK1 inhibitor RI-962 with an unreported scaffold
A target-conditioned generative deep-learning model based on a distribution-learning conditional recurrent neural network generated a tailored compound library that was screened for RIPK1 inhibition. The study reports RI-962 as a potent inhibitor with a previously unreported scaffold, validated in vitro for protection from necroptosis and in vivo in two inflammatory models.
Technology: Generative deep-learning distribution-learning conditional recurrent neural network (GDL cRNN)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The study reports RI-962 as a potent inhibitor with a previously unreported scaffold, validated in vitro for protection from necroptosis and in vivo in two inflammatory models.
- Still unknown: Evidence is preclinical: cellular necroptosis assays and two inflammatory mouse models do not establish human efficacy or safety. The paper identifies one leading molecule from a generated library; it does not validate generative-model performance across targets generally.
- AI role: The GDL cRNN generated a target-tailored virtual compound library; virtual screening and subsequent chemical synthesis and bioactivity assays selected RI-962. This provides direct experimental testing of a model-generated molecule rather than a prediction-only hit.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/36371441/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 114 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.